Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?
Nephrology Dialysis Transplantation · 2023
DOI: 10.1093/ndt/gfac284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von L Parker Gregg und 1 weiteren Autor:innen. Beteiligte Einrichtung: Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Heart Failure, Hyperkalemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, NHLBI NIH HHS, HSRD VA.
Abstract (Originalsprache)
Renin–angiotensin–aldosterone system inhibitors (RAASi) and mineralocorticoid receptor antagonists (MRAs) are important interventions to improve outcomes in patients with chronic kidney disease and heart failure, but their use is limited in some patients by the development of hyperkalemia. The risk of hyperkalemia may differ between agents, with one trial showing lower risk of hyperkalemia with the novel non-steroidal MRA finerenone compared with steroidal MRA spironolactone. Novel potassium binders, including patiromer and sodium zirconium cyclosilicate, are available interventions to manage hyperkalemia and enable continuation of RAASi and MRAs in patients who could benefit from these treatments. These agents bind free potassium ions in the lumen of the gastrointestinal tract to prevent the absorption of dietary potassium and increase potassium secretion. Several studies showed that potassium binders are effective compared with placebo for preventing hyperkalemia or steroidal MRA discontinuation, but none has evaluated whether this strategy impacts clinically important endpoints such as cardiovascular events. Due to this and other limitations related to cost, clinical availability, pill burden and patient selection, alternative potential strategies to mitigate hyperkalemia may be more practical. Conservative strategies include increased monitoring and use of loop or thiazide diuretics to increase urinary potassium excretion. Non-steroidal MRAs may have a lower risk of hyperkalemia than steroidal MRAs and have stronger anti-inflammatory and anti-fibrotic effects with resultant reduced risk of kidney disease progression. Sodium-glucose cotransporter-2 inhibitors also decrease hyperkalemia risk in patients on MRAs and decrease cardiovascular events and kidney disease progression. These may be better first-line interventions to obviate the need for potassium binders and offer additional benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
- Section of Nephrology, Medical Care Line, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA.
- Veterans Affairs Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, TX, USA.
- Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
Förderung
- CSRD VA
- NHLBI NIH HHS
- HSRD VA
- VA CSR&D Career Development Award
- Houston VA Health Services Research & Development Center for Innovations
- Department of Veterans Affairs Health Services Research & Development
- NIH
- Veterans Administration
Zitieren
APA
Gregg, L. P., & Navaneethan, S. D. (2023). Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac284
Vancouver
Gregg LP, Navaneethan SD. Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac284
BibTeX
@article{Gregg2023,
author = {Gregg, L Parker and Navaneethan, Sankar D},
title = {Steroidal or non-steroidal MRAs: should we still enable RAASi use through K binders?},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
doi = {10.1093/ndt/gfac284}
}
EUVIMED